🔔Stock Alerts via Telegram — Free for All Users

ELV Stock Risk & Deep Value Analysis

Elevance Health Inc

DVR Score

0.8

out of 10

Distressed

What You Need to Know About ELV Stock

We analyzed Elevance Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ELV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated May 1, 2026Run Fresh Analysis →

ELV Risk Analysis & Red Flags

What Could Go Wrong

The actual financial exposure from the CMS Medicare Advantage data reporting issue could significantly exceed the $935 million accrual, potentially leading to further large charges or fines that materially impact future earnings and cash flow beyond current estimates, causing investor uncertainty and a stock decline.

Risk Matrix

Overall

Moderate

Financial

Medium

Market

Low

Competitive

Medium

Execution

Medium

Regulatory

High

Red Flags

  • The $935 million accrual for potential CMS Medicare Advantage data reporting exposure is a significant financial hit.

  • GAAP diluted EPS was down YoY in Q1 2026 despite adjusted EPS beat.

  • Benefit ratio increased by 40 bps YoY, indicating higher medical costs relative to premiums.

  • Membership declines in key segments like Medicare Advantage and Medicaid.

Upcoming Risk Events

  • 📅

    Negative resolution or higher penalties related to CMS Medicare Advantage data reporting exposure

  • 📅

    Significant increases in benefit ratio due to higher medical costs

  • 📅

    Adverse changes in government healthcare policy or reimbursement rates

When to Reconsider

  • 🚪

    Exit if the company significantly downgrades its full-year EPS or cash flow guidance.

  • 🚪

    Sell if the benefit ratio continues to rise above 87-88% for consecutive quarters.

  • 🚪

    Exit if a definitive regulatory ruling imposes penalties significantly higher than the current accrual.

Unlock ELV Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Elevance Health is a well-established, financially robust leader in the mature U.S. healthcare sector, offering stable, defensive growth and reliable dividends. Its strategic focus on expanding integrated Carelon services, strong operating cash flow generation, and consistent capital returns make it an attractive holding for income-focused or conservative growth investors, though it lacks the disruptive potential for a 10x return within the specified timeframe.

Is ELV Stock Undervalued?

Elevance Health remains a dominant, financially robust player in the mature healthcare insurance market. Its Q1 2026 performance showed a beat on adjusted EPS and raised FY26 guidance, supported by strong operating cash flow and continued growth in the Carelon services segment (+7.9% YoY). However, these positives are tempered by a significant $935 million accrual for potential CMS Medicare Advantage data reporting exposure, a decline in GAAP EPS YoY, and a rising benefit ratio. While the company's strategic focus on integrated 'whole health' and Carelon is sound for maintaining leadership and driving stable growth, these initiatives, along with its current large market capitalization of $81.74B, do not position it for a 10x return within 3-5 years. It is a solid, defensive investment rather than a high-risk, high-reward exponential growth opportunity. The new Q1 earnings and related disclosures do not materially alter its 10x growth potential from the previous assessment, hence the consistent low score.

Unlock the full AI analysis for ELV

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

ELV Price Targets & Strategy

12-Month Target

$420.00

Bull Case

$455.00

Bear Case

$320.00

Valuation Basis

Based on 15.7x forward P/E applied to est. FY26 adjusted EPS of $26.75

Entry Strategy

Consider dollar-cost averaging between $350-$365, near recent support levels, to accumulate shares for long-term defensive positioning.

Exit Strategy

Consider taking partial profits if the stock reaches $420-$450. A stop-loss could be placed if the stock consistently trades below $330, indicating a breakdown in fundamental or technical support.

Portfolio Allocation

3-7% for moderate risk tolerance, reflecting its defensive nature and stable growth profile.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is ELV Financially Healthy?

Valuation

P/E Ratio

15.44

Forward P/E

11.23

Profitability

Operating Margin

3.81%

Net Margin

2.62%

Return on Equity

11.95%

Revenue Growth

9.44%

EPS

$23.51

Balance Sheet

Current Ratio

0.19

Quick Ratio

0.19

Debt/Equity

0.73

Other

Beta (Volatility)

0.66

Dividend Yield

1.83%

Does ELV Have a Competitive Moat?

Sign in to unlock

Moat Rating

🏰 Wide

Moat Trend

Stable

Moat Sources

4 Identified

Efficient ScaleSwitching CostsIntangible Assets/IPNetwork Effects

Elevance Health's moat is highly durable due to the heavily regulated nature of the healthcare insurance industry, requiring immense capital and licenses to operate at scale. Its vast provider networks and brand reputation also create high switching costs for large clients and members, ensuring sustained market presence and profitability.

Moat Erosion Risks

  • Increased government intervention or push for single-payer healthcare systems.
  • Potential for significant regulatory changes that could alter reimbursement models or operational requirements.
  • Intensified competition leading to pricing pressure and erosion of margins.

ELV Competitive Moat Analysis

Sign up to see competitive advantages

ELV Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (Large, mature company; less retail discussion for high growth)

Institutional Sentiment

Neutral to Positive (Q1 adjusted EPS beat and raised guidance likely maintain positive sentiment, but CMS accrual adds caution).

Insider Activity (Form 4)

No specific Form 4 filings reported in last 90 days (Feb 1-Apr 30, 2026); no CEO/CFO activity flagged.

Options Flow

Normal options activity (No specific unusual activity reported in the research).

Earnings Intelligence

Next Earnings

Estimated early-July 2026 (for Q2 2026)

Surprise Probability

Medium

Historical Earnings Pattern

Elevance Health typically sees a modest positive reaction to adjusted EPS beats and guidance raises. However, significant non-recurring charges or regulatory news can temper enthusiasm.

Key Metrics to Watch

Operating revenue growth (especially Carelon segment)Adjusted diluted EPS and GAAP diluted EPSBenefit ratio and operating margin trendsUpdates on CMS Medicare Advantage data reporting exposureMembership trends by segment (Medicare Advantage, Medicaid, Commercial)

Competitive Position

Top Competitor

UNH

Market Share Trend

Stable (Mixed membership trends, with declines in MA/Medicaid offset by growth in commercial fee-based and ACA segments, leading to a small overall increase).

Valuation vs Peers

Trading at a comparable or slight discount to its closest peers like UnitedHealth Group on a P/E basis, reflecting its slightly slower diversified growth profile.

Competitive Advantages

  • Vast provider networks and established brand recognition across multiple states.
  • Significant scale providing cost advantages and bargaining power.
  • Integrated Carelon services offering a diversified revenue stream beyond traditional insurance.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive ELV Stock Higher?

Near-Term (0-6 months)

  • Q2 2026 Earnings (Expected July 2026)
  • Further updates/clarification on CMS Medicare Advantage data reporting exposure

Medium-Term (6-18 months)

  • Continued expansion and market penetration of Carelon services segment
  • Successful execution of 'whole health' integrated care models

Long-Term (18+ months)

  • Demographic tailwinds for healthcare demand (aging population)
  • Increased adoption of value-based care models across the industry

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ELV?

  • Acceleration in Carelon segment revenue growth rates above current trends.

  • Consistent improvement and stabilization of the benefit ratio.

  • Favorable resolution of the CMS Medicare Advantage data reporting exposure.

Bull Case Analysis

See what could go right with Premium

Competing with ELV

See how Elevance Health Inc compares to related companies

CompanyMarket CapDVR ScoreP/ERevenueProfit MarginRev Growth

Elevance Health Inc

ELV

$80.9B0.815.42.6%9.4%

UnitedHealth Group Inc

UNH

$276.2B0.322.9$113.7B2.7%1181.0%Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

How Elevance Health Inc Makes Money

Elevance Health primarily generates revenue by providing health insurance benefits to millions of members across various types of plans, including employer-sponsored, Medicaid, Medicare Advantage, and individual Affordable Care Act (ACA) plans, mainly in over a dozen U.S. states. They collect premiums from members and employers, then manage the associated healthcare costs. A growing portion of their business comes from their Carelon services segment, which provides integrated health solutions like pharmacy benefits management, behavioral health, clinical care, and digital tools, not only to their own insurance members but also to external clients, aiming to improve health outcomes and reduce overall healthcare spending.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Elevance Health Inc (ELV)?

As of May 1, 2026, Elevance Health Inc has a DVR Score of 0.8 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Elevance Health Inc?

Elevance Health Inc's market capitalization is approximately $80.9B..

What is the risk level for ELV stock?

Our analysis rates Elevance Health Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of ELV?

Elevance Health Inc currently has a price-to-earnings (P/E) ratio of 15.4. This is in line with broader market averages.

Does Elevance Health Inc pay a dividend?

Yes, Elevance Health Inc pays a dividend with a current yield of approximately 1.83%.

Is Elevance Health Inc's revenue growing?

Elevance Health Inc has reported revenue growth of 9.4%. The company is growing at a moderate pace.

Is ELV stock profitable?

Elevance Health Inc has a profit margin of 2.6%. The company is profitable but margins are modest.

How often is the ELV DVR analysis updated?

Our AI-powered analysis of Elevance Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 1, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ELV (Elevance Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to ELV Stock Risk & Deep Value Analysis